Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 8

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 8
---
 this offering. Although our Class A common stock has been listed on the Nasdaq Global Market since May 14, 2021, an
active trading market for our shares may not be sustained in the future. If an active market for our Class A common stock is not sustained, it may be difficult for you to sell shares you purchased in this offering at an attractive price or at
all.

In addition, certain existing stockholders of our company and their affiliates may purchase shares of Class A common stock being sold by the Company in
this offering at the public offering price and on the same terms as the other shares of Class A common stock being offered.

This concentration of ownership by
our existing stockholders may result in fewer shares being actively traded in the public market because these stockholders may be restricted from selling such shares under applicable securities laws, which could reduce the liquidity of the market
and the available public float for our shares of Class A common stock.

S-6

Special note regarding forward-looking statements

This prospectus supplement and accompanying prospectus, including the information incorporated by reference herein and therein, contain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act, and the Private Securities Litigation Reform Act of 1995, as amended, that involve substantial risks and
uncertainties. All statements contained in this prospectus supplement and accompanying prospectus regarding future events, results or outcomes, including our future results of operations and financial position, business strategy, research and
development costs, the anticipated timing, costs and conduct of our planned clinical trials for our product candidates, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our
product candidates, if approved, the pricing and reimbursement of our product candidates, if approved, the potential benefits of strategic collaborations and our ability to enter into strategic arrangements, timing and likelihood of success, plans
and objectives of management for future operations, and future results of anticipated products are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This prospectus supplement, the accompanying prospectus and the documents
incorporated by reference herein and therein also contain estimates and other statistical data made by independent parties and by us relating to market size and growth